“A white space opportunity.” That’s how Enlaza Therapeutics Inc. co-founder and CEO Sergio Duron described to BioWorld the company’s efforts to develop the first covalent biologics, an endeavor that has gained the backing of an impressive group of investors in a recently closed $100 million series A round. Read More
Scientists from the Centre for Genomic Regulation and collaborators have developed a new approach to limiting the amount of collagen produced by hyperactive fibroblasts, which could lead to effective treatments for fibrotic diseases and scarring. Read More
Irlab Therapeutics AB has obtained clearance from the Swedish Medical Products Agency to initiate a phase I study of IRL-757, which is being developed as a treatment to counteract apathy in Parkinson’s disease and other neurological conditions. Read More
Autoantibodies can promote inflammation and activate complement pathways and immune cell responses causing tissue damage in autoantibody-driven diseases. Researchers from Seismic Therapeutic Inc. have presented data on S-1117. Read More
Schepens Eye Research Institute presented new preclinical data on its AAV2.sFasL gene therapy, an adeno-associated virus (AVV2) encoding soluble Fas ligand (sFasL) for the potential prevention of glaucoma. Read More
The recent cyberattack on Change Healthcare, a part of the Unitedhealth Group, crippled reimbursement claims processing for thousands of providers for several weeks and potentially exposed troves of patient data. Congressional committees are investigating the attack, its scope, and Unitedhealth’s response. Please take a few minutes to fill out this short survey to help BioWorld understand how your company is responding to these threats. You can click through to the questions here. Read More
Amicetin-inspired inhibitors of the P-site (AIIPS), also known as CZ-02s, are a series of molecules that target and inhibit a unique site of the bacterial ribosome. Read More
Chemokine CXCL5 is an inflammatory mediator and a powerful neutrophil chemoattractant, which mainly acts through CXCR2 to produce its biological effects. Read More
Hanmi Holdings Co. Ltd. has disclosed transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer. Read More
There is a compelling need to produce new antibiotics that hamper severe opportunistic infections, especially in immunocompromised individuals, such as those caused by gram-negative Pseudomonas aeruginosa. Read More
Researchers at Biodol Therapeutics SAS, Centre National de la Recherche Scientifique, INSERM and Université de Strasbourg have divulged new n-heteroarylbenzamide derivatives acting as FLT3 (FLK2/STK1) inhibitors and reported to be useful for the treatment of pain. Read More
Researchers from Peptidream Inc. presented preclinical characterization of novel carbonic anhydrase IX (CAIX)-targeting radiopeptides, [64Cu]PD-32766 and [177Lu]PD-32766, being developed for the diagnosis and treatment of clear cell renal cell carcinoma (ccRCC), respectively. Read More
